Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
159 hedge funds and large institutions have $286M invested in Clovis Oncology, Inc. in 2020 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 50 increasing their positions, 44 reducing their positions, and 35 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 44
6% less funds holding
Funds holding: 169 → 159 (-10)
10% less capital invested
Capital invested by funds: $318M → $286M (-$32.3M)
24% less call options, than puts
Call options by funds: $19.8M | Put options by funds: $26.1M
26% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 35
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$24.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.12M |
| 3 |
BlackRock
New York
|
+$4.5M |
| 4 |
Millennium Management
New York
|
+$3.88M |
| 5 |
AC
Armistice Capital
New York
|
+$2.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$6M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$5.83M |
| 3 |
N
Natixis
Paris,
France
|
-$5.41M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$4.31M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.56M |
CLVS Hedge Fund Activity: Q4 2020 in Review
159 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q4 2020, worth a combined $286M — down 10% from $318M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of CLVS and 26 opened new positions — a net loss of 9 holders — while 44 trimmed existing stakes and 50 added.
The largest buyer was State Street, adding an estimated $24.7M. The largest seller was Morgan Stanley, cutting an estimated $6M.
- 159 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q4 2020, down from 169 in Q3 2020.
- Funds reported $286M of Clovis Oncology, Inc. stock for Q4 2020, down 10% quarter-over-quarter.
- 26 funds opened new Clovis Oncology, Inc. positions in Q4 2020 and 35 closed out, a net change of -9 holders.
- The largest Clovis Oncology, Inc. buyer in Q4 2020 was State Street, an estimated $24.7M added.
- The largest Clovis Oncology, Inc. seller in Q4 2020 was Morgan Stanley, an estimated $6M sold.
Based on aggregated 13F filings for Q4 2020.